Neuropeptide Localization in the ‘Migraine Generator’ Region of the Human Brainstem

Cephalalgia - Tập 21 Số 2 - Trang 96-101 - 2001
János Tajti1, Rolf Uddman2, Lars Edvinsson3
1Department of Neurology, Albert Szent-Györgyi University Medical School, Szeged, Hungary
2Department of Otorhinolaryngology, Malmö University Hospital, Malmö, Sweden
3Department of Internal Medicine, Lund University Hospital, Lund, Sweden

Tóm tắt

Evidence from animals and humans suggests that brainstem nuclei such as the raphe nuclei, the locus coeruleus (LC) and the periaqueductal grey matter (PAG), are involved in the pathophysiology of migraine. In order to understand possible neurotransmitters involved we have, by means of indirect immunocytochemistry, analysed these regions for the occurrence and distribution of calcitonin gene-related peptide (CGRP), substance P (SP), pituitary adenylate-cyclase activating peptide (PACAP) and vasoactive intestinal polypeptide (VIP). CGRP-immunoreactive (-ir) cell bodies, but no fibres, were found to occur in high numbers, constituting 80% of all nerve cell bodies in the LC. A smaller number of these nerve cell bodies (40%) in the LC proved to be PACAP-ir. The LC neurones also stored the vesicular monoamine transporter (VMAT)- and the C-terminal flanking peptide of neuropeptide Y (C-PON)-ir, illustrating their adrenergic nature. Double immunostaining revealed that all VMAT-and C-PON-containing neurones, in addition, stored CGRP. Immunoreactive cell bodies were not seen in the nucleus raphe magnus (NRM) or PAG. Numerous SP-ir nerve fibres were observed in the NRM, the LC and the PAG. Few PACAP-ir nerve fibres were detected in the PAG and few VIP-ir nerve fibres were seen in the NRM and the PAG.

Từ khóa


Tài liệu tham khảo

10.1093/acprof:oso/9780192618108.003.0003

2 Davidoff RA. Migraine: manifestations, pathogenesis and management. Philadelphia: FA Davis Co., 1995:115–80.

3 Silberstein SD, Lipton RB, Goadsby PJ. Headache in clinical practice. Oxford: Isis Medical Media, 1998:41–90.

10.1111/j.1526-4610.1983.hed2306258.x

10.1038/nm0795-658

Diener HC, 1996, Migraine: pharmacology and genetics., 109

10.1111/j.1526-4610.1987.hed2708416.x

10.1046/j.1526-4610.1997.3710622.x

10.1177/0333102499019S2304

10.1097/00019052-199706000-00012

10.1136/jnnp.64.2.143

10.1002/ana.410280213

10.1002/ana.410330109

Sundler F, 1985, Tachykinin antagonists., 3

10.1016/0306-4522(93)90018-B

10.1016/0306-4522(92)90064-9

10.1016/0167-0115(95)00114-5

10.1046/j.1468-1331.1998.540329.x

10.1016/0891-0618(91)90020-D

10.1016/0143-4179(88)90010-8

10.1016/0006-8993(90)90603-9

10.1016/0006-8993(79)90942-9

10.1002/cne.901780203

10.1007/BF00235282

10.1002/cne.901570104

Fields HL, 1999, Textbook of pain., 300

10.1038/jcbfm.1993.36

10.1016/0014-2999(95)00404-9

10.1016/0014-2999(95)00011-9

10.1210/jcem-72-5-958

10.1016/0006-8993(95)00869-R

10.1002/syn.890020403

10.1016/0006-8993(95)00632-Z

10.1002/ana.410160202

10.1523/JNEUROSCI.07-12-04129.1987

10.1046/j.1468-2982.1997.1707785.x

10.1016/S0143-4179(97)90038-X

10.1016/S0165-6147(99)01396-6

10.1523/JNEUROSCI.03-07-01437.1983

10.1002/cne.903500103